This is a review article and it gives some views on targeting a cure. There is alot of hope on CAR-T therapy of B cells, but is it anybetter than B cell depletion. This paper doesnt give that answer but perhaps you could try and answer it with available technology. Maybe if they could read our paper
Marta M, Baker D, Creeke P, Pryce G, Gnanapavan S, Giovannoni G. Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report. Mult Scler Relat Disord. 2021 Nov;56:103284.
One swallow doesnt create a summer but it was robust in animals. Is CAR-T therapy the answer…I don’t know but it has potential
Isaacs JD. Immune reset and immune retune: approaching cure? Nat Rev Rheumatol. 2026 Feb 16. doi: 10.1038/s41584-026-01357-7.
The emergence of potent depletion therapies for the treatment of refractory autoimmunity has led to the concept of immune reset. Understanding whether immune reset equates to cure, and whether cure is achievable through non-depleting approaches, depends on the identification of immune biomarkers for measuring healthy and pathological immunity.
Autoimmunity has traditionally been considered a ‘one-way street’ with no reversibility and, accordingly, treatment has comprised immunosuppressive and anti-inflammatory drugs, with the aim of suppressing symptoms and preventing damage. Although the possibility of cure through the use of immunomodulatory therapies first emerged from preclinical models four decades ago, clinical translation has been slow Autologous and, in some instances…has provided drug-free, long-term remission for a proportion of patients. In the past 5 years, however, encouraging early results of deep B cell depletion through the use of chimeric antigen receptor (CAR) T cell therapy and other modalities have led to increasing use of the term ‘immune reset’ (or ‘B cell reset’). However, in this context, what defines reset? Does it equate to cure, and are there alternative routes to resetting autoimmunity?
“Even rituximab, which is now regarded as a relatively weak B cell-depleting therapy, can provide sustained benefit in some patients” Check out Prof Peihl data from Sweden
“The ‘elephant in the room’ of this discussion is the inability to identify and specifically eradicate disease-causing B cell clones”. Speak to Prof Angry he can tell you how to do it:)
Doing it in arthritis or multiple sclerosis is not the best way forward
Source: multiple-sclerosis-research.org